<DOC>
	<DOCNO>NCT00221312</DOCNO>
	<brief_summary>This study determine Fosamax ( alendronate ) , medication approve Food Drug Administration ( FDA ) prevention treatment osteoporosis postmenopausal woman , effective decrease rate bone loss often begin increase three five year precede menopause ( perimenopausal transition ) . During three five year prior menopause , rate bone loss increase . One way physicians treat oral contraceptive medication . However , incidence complication oral contraceptive age 40 increase . Therefore , non-hormonal mean prevent bone loss useful . Fosamax ( alendronate ) class compound call bisphosphonates . This study do determine whether Fosamax use prevent increase rate bone loss perimenopausal transition .</brief_summary>
	<brief_title>Fosamax Bone Loss Study : Alendronate Prevent Bone Loss</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Women age 4054 symptomology perimenopause include hot flash , irregular period vaginal dryness . Women hormone replacement , oral contraceptive , bone mineral enhance medication ( bisphosphonates , selective estrogen receptor modulators [ SERM 's ] , parathyroid hormone [ PTH ] , calcitriol , fluoride ) They abnormalities esophagus delay esophageal empty They hypocalcemia severe kidney disease Their bone mineral density ( Tscore ) great 2 standard deviation .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>Perimenopausal bone loss</keyword>
</DOC>